Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâ€™s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.

Employees

Sector

Biotechnology & Medical Research

More about the company

07-15	Heidelberg Pharma AG Reports Earnings Results for the Half Year Ended May 31, 2026	CI
06-23	Heidelberg Pharma Ag Approves the Election of Mr. Jack Yefei Ling as New Member of the Supervisory Board	CI

Market Cap	118M 138M 111M 101M 191M 13.19B 194M 1.3B 511M 6.61B 518M 507M 21.87B	P/E 2026 *	-4.87x	P/E 2027 *	-5.04x
Enterprise Value	110M 129M 103M 94.61M 178M 12.31B 181M 1.22B 476M 6.17B 483M 473M 20.41B	EV / Sales 2026 *	11x	EV / Sales 2027 *	7.78x
Free-Float	21%	Yield 2026 *	-	Yield 2027 *	-

07-15	Heidelberg Pharma AG Reports Earnings Results for the Half Year Ended May 31, 2026	CI
06-23	Heidelberg Pharma Ag Approves the Election of Mr. Jack Yefei Ling as New Member of the Supervisory Board	CI
04-30	Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 28, 2026	CI
04-17	Heidelberg Pharma AG Announces Chief Financial Officer Changes	CI
04-09	Heidelberg Pharma Sets Dose for Mid-stage Trial of Multiple Myeloma Drug Candidate	MT
04-09	Heidelberg Pharma AG Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101	CI
04-04	Heidelberg Pharma AG Presents Data from Its ADC Technology Platform At AACR Annual Meeting	CI
03-31	Heidelberg Pharma AG, 2025 Earnings Call, Mar 26, 2026
03-26	Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2025	CI
03-26	Heidelberg Pharma AG Provides Earnings Guidance for the Fiscal Year 2026	CI
03-18	Heidelberg Pharma Set to Get Milestone Payment for Plasma Cell Disorders Treatment Clinical Study	MT
03-18	Heidelberg Pharma AG Receives Milestone Payment for Clinical Study with HDP-101 in China	CI
03-07	Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement	RE

07-15	SIMRIS GROUP AB APPOINTS ADC EXPERT PROFESSOR ANDREAS PAHL AS CHIEF EXECUTIVE OFFICER OF ITS SUBSIDIARY SIMRIS BIOLOGICS GMBH	AQ
07-15	Heidelberg Pharma Reports on First Half-Year 2026 and the Positive Course of Business	EQ
06-23	Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026	EQ
05-13	Heidelberg Pharma : Explanations on the resolutionless agenda item 1 (HDP ExplanationItem1)	PU
05-13	Heidelberg Pharma : CV of the proposed Supervisory Board candidate (202605 CV AR 2026 engl)	PU

07-15	Heidelberg Pharma berichtet über das erste Halbjahr 2026 und positiven Geschäftsverlauf
07-10	Unternehmenskalender vom 13. bis 17. Juli 2026
06-23	Heidelberg Pharma : Voting results (HPHA Abstimmung Liste copy 1)
06-23	Heidelberg Pharma : Abstimmungsergebnisse (HPHA Abstimmung Liste)
06-23	Heidelberg Pharma berichtet über die Ergebnisse der ordentlichen Hauptversammlung 2026

Wilex AG Stock Xetra

Stocks

DE0006614720

Biotechnology & Medical Research

Valuation: Wilex AG

Latest news : Wilex AG

Last Transcript: Wilex AG

Analysts' recommendations: Wilex AG

Press Releases: Wilex AG

News in other languages: Wilex AG

Managers and Directors: Wilex AG

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Dong Zhou Liu CEO	Chief Executive Officer	-	24/11/2025
Peter Willinger DFI	Director of Finance/CFO	-	01/05/2026
András Strassz CTO	Chief Tech/Sci/R&D Officer	-	01/03/2021

Director	Title	Age	Since
Georg F. Baur CHM	Chairman	76	14/12/2000
Birgit Kudlek BRD	Director/Board Member	59	25/05/2012
Mathias Hothum BRD	Director/Board Member	58	30/07/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-1.90%	+2.37%	+69.11%	+110.88%	73.45B
ARGENX SE	+0.87%	+17.17%	+53.05%	+95.59%	62.99B
INSMED INCORPORATED	+1.49%	-2.39%	+1.50%	+486.91%	28.05B
WUXI BIOLOGICS (CAYMAN) INC.	-1.40%	+4.18%	+54.52%	+19.60%	25.42B
BIONTECH SE	+22.19%	+20.46%	+0.28%	-4.95%	23.3B
GENMAB A/S	+2.28%	+5.65%	+42.00%	-13.75%	19.45B
PHARMAESSENTIA CORPORATION	0.00%	-4.11%	+243.99%	+423.83%	18.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.50%	-0.95%	+17.17%	+534.55%	16.53B
EXELIXIS, INC.	+2.32%	+7.86%	+44.83%	+154.28%	13.16B
Average	+2.47%	+2.74%	+58.49%	+200.77%	31.17B
Weighted average by Cap.	+1.61%	+4.39%	+56.95%	+165.78%

	2026 *	2027 *
Net sales	10M 11.66M 9.34M 8.57M 16.11M 1.11B 16.38M 110M 43.15M 559M 43.77M 42.82M 1.85B	13M 15.16M 12.14M 11.14M 20.94M 1.45B 21.29M 143M 56.09M 726M 56.9M 55.67M 2.4B
Net income	-24.3M -28.33M -22.69M -20.82M -39.15M -2.71B -39.79M -268M -105M -1.36B -106M -104M -4.49B	-23.5M -27.4M -21.94M -20.13M -37.86M -2.62B -38.48M -259M -101M -1.31B -103M -101M -4.34B
Net Debt	-7.93M -9.24M -7.4M -6.79M -12.77M -883M -12.98M -87.36M -34.21M -443M -34.7M -33.95M -1.46B	-17.24M -20.09M -16.09M -14.77M -27.77M -1.92B -28.22M -190M -74.36M -963M -75.44M -73.8M -3.18B

End-of-day quote Xetra
- ^EUR	-